Physician profile
Arash Vahdat
NPI 1225134232
$87,602.63
in general payments reported to CMS, 2019-2025
40 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $9,434 · 2021: $19K · 2022: $9,634 · 2023: $9,471 · 2024: $5,601 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $7,622 · Travel and Lodging: $1,003 · Consulting Fee: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,668.00 |
| Food and Beverage | $7,622.35 |
| Travel and Lodging | $1,003.29 |
| Consulting Fee | $425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46,706.41 | 2019-2025 | Repatha, Repatha, Tepezza |
| Abbott Laboratories | $29,825.83 | 2019-2025 | Aveir, Gallant, Assurity |
| Novartis Pharmaceuticals Corporation | $1,358.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,127.68 | 2019-2023 | Xarelto |
| Pfizer INC. | $837.39 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $815.91 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $700.45 | 2019-2025 | Farxiga, Andexxa, Wainua |
| Sanofi-Aventis U.S. LLC | $657.66 | 2019-2024 | |
| Medtronic Vascular, INC. | $557.54 | 2019-2020 | |
| Boston Scientific Corporation | $556.48 | 2020-2025 | Emerge Push, Rotapro, General - Atherectomy |
| Bayer Healthcare Pharmaceuticals INC. | $453.63 | 2021-2025 | |
| Esperion Therapeutics, INC. | $445.88 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $441.39 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $407.27 | 2019-2025 | Impella |
| Amarin Pharma, INC. | $352.14 | 2020-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.25 | 2022-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $300.92 | 2021-2025 | Onpattro, Amvuttra |
| Medtronic, INC. | $225.24 | 2021-2025 | Selectsecure, Micra, Azure Xt Dr Mri Surescan |
| Heartflow, INC. | $195.67 | 2022-2025 | Ffrct |
| Biotronik INC. | $174.98 | 2019-2025 | Amvia Edge, Biomonitor |
| Edwards Lifesciences Corporation | $145.06 | 2022-2023 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $124.94 | 2022-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $107.38 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $97.56 | 2025 | Attruby |
| Novo Nordisk INC | $92.22 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $84.46 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $75.95 | 2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $75.20 | 2024 | Assure Wcd |
| Gilead Sciences, INC. | $43.55 | 2019 | |
| Shockwave Medical, INC | $36.41 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $34.64 | 2023 | Arcalyst |
| Cardiovascular Systems INC. | $28.42 | 2019 | |
| Bardy Diagnostics, INC. | $25.00 | 2022 | |
| Lilly USA, LLC | $24.24 | 2020 | |
| Altathera Pharmaceuticals LLC | $24.12 | 2025 | Sotalol Hydrochloride |
| Glaxosmithkline, LLC. | $23.76 | 2025 | Arexvy, Shingrix |
| Cvrx, INC. | $22.89 | 2024 | Barostim Neo System |
| Aegerion Pharmaceuticals, INC. | $18.87 | 2019 | |
| Elutia, INC. | $17.94 | 2021 | |
| Tactile Systems Technology INC | $14.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Vahdat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.